{"transactions":[{"id":900295,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":66146,"kind":"person","name":"Casper Joseph Michael","position":1,"cik":"0002106955","reported_name":"Casper Joseph Michael","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:00:43.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027."}],"balance_after":100000,"derivative":{"exercise_price":2.39,"expiration_date":"2036-01-27","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001437749-26-004426","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926004426/rdgdoc.xml","form_type":"4"}},{"id":1043894,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and Chief Scientist"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:36:07.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued"}],"balance_after":125000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-024084","document":"form4-09102025_070903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588925024084/form4-09102025_070903.xml","form_type":"4"}},{"id":1044169,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75591,"kind":"person","name":"McBride Dennis","position":1,"cik":"0002028250","reported_name":"McBride Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:35:32.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-024083","document":"form4-09102025_070927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028250/000141588925024083/form4-09102025_070927.xml","form_type":"4"}},{"id":1043756,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:35:00.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-024082","document":"form4-09102025_070956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000141588925024082/form4-09102025_070956.xml","form_type":"4"}},{"id":1044092,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:34:21.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-024081","document":"form4-09102025_070918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588925024081/form4-09102025_070918.xml","form_type":"4"}},{"id":1273795,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":83364,"kind":"person","name":"ABRAMS MICHAEL S","position":1,"cik":"0001497702","reported_name":"ABRAMS MICHAEL S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-11T17:00:05.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest in three equal annual installments beginning on February 7, 2026."}],"balance_after":50000,"derivative":{"exercise_price":2.94,"expiration_date":"2035-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-003585","document":"form4-02112025_050201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1497702/000141588925003585/form4-02112025_050201.xml","form_type":"4"}},{"id":1326487,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and Chief Scientist"}}],"security":"Common Stock","published_at":"2024-12-18T08:27:36.000Z","date":"2024-12-17","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":1.17,"value":46800.0,"ownership":{"direct":true},"balance_after":84634,"source":{"system":"sec-edgar","filing":"0001415889-24-029694","document":"form4-12182024_011233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588924029694/form4-12182024_011233.xml","form_type":"4"}},{"id":1783994,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-09-11T09:19:33.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":35000,"price":0.3199,"value":11196.5,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 8,336 shares of Common Stock held by Samuel David Gorovitz 2017 Irrevocable Trust, (ii) 8,336 shares of Common Stock held by Jeremy Paul Gorovitz 2017 Irrevocable Trust, (iii) 8,336 shares of Common Stock held by Marisa Shey Gorovitz 2017 Irrevocable Trust, (iv) 51,678 shares of Common Stock held by Elizabeth Gorovitz. Aaron Gorovitz is the trustee of the Samuel David Gorovitz 2017 Irrevocable Trust, the Jeremy Paul Gorovitz 2017 Irrevocable Trust, and the Marisa Shey Gorovitz 2017 Irrevocable Trust. Elizabeth Gorovitz is the wife of Aaron Gorovitz;"}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0001415889-23-013139","document":"form4-09112023_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000141588923013139/form4-09112023_010928.xml","form_type":"4"}},{"id":1783645,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-09-11T09:15:13.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":70000,"price":0.2875,"value":20125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The\nReporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":570000,"source":{"system":"sec-edgar","filing":"0001415889-23-013137","document":"form4-09112023_010907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000141588923013137/form4-09112023_010907.xml","form_type":"4"}},{"id":1797554,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2023-08-24T12:14:01.000Z","date":"2023-08-23","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.33,"value":33000.0,"ownership":{"direct":true},"balance_after":446332,"source":{"system":"sec-edgar","filing":"0001104659-23-094815","document":"tm2324394-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000110465923094815/tm2324394-3_4seq1.xml","form_type":"4"}},{"id":1798555,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2023-08-23T09:24:41.000Z","date":"2023-08-22","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.322,"value":64400.0,"ownership":{"direct":true},"balance_after":346332,"source":{"system":"sec-edgar","filing":"0001104659-23-094406","document":"tm2324394-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000110465923094406/tm2324394-1_4seq1.xml","form_type":"4"}},{"id":2015903,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-02-14T17:14:37.000Z","date":"2022-12-14","kind":"gift","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Donation of 300,000 shares from the Jonathan Javitt Living Trust to the Jonathan Javitt Donor Advised Fund."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Charitable Transfer"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund.  Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund."}],"balance_after":14468329,"source":{"system":"sec-edgar","filing":"0001415889-23-002500","document":"form5-02142023_100203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588923002500/form5-02142023_100203.xml","form_type":"5"}},{"id":2081283,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":32058,"kind":"person","name":"Willard Stephen H","position":1,"cik":"0001325232","reported_name":"Willard Stephen H","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-19T12:14:23.000Z","date":"2022-12-16","kind":"purchase","acquired":true,"shares":50000,"price":1.17,"value":58500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001415889-22-012654","document":"form4-12192022_121215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325232/000141588922012654/form4-12192022_121215.xml","form_type":"4"}},{"id":2081597,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-19T07:09:44.000Z","date":"2022-12-16","kind":"purchase","acquired":true,"shares":30000,"price":1.1,"value":33000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":46337,"source":{"system":"sec-edgar","filing":"0001415889-22-012652","document":"form4-12192022_121236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922012652/form4-12192022_121236.xml","form_type":"4"}},{"id":2081413,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-19T07:08:15.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":7021,"price":1.11,"value":7793.31,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total number of shares held is reduced by 40 shares to correct an arithmetic error in the original Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The form of ownership has been changed from Indirect to Direct.  The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error."}],"balance_after":16337,"source":{"system":"sec-edgar","filing":"0001415889-22-012650","document":"form4a-12192022_121206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922012650/form4a-12192022_121206.xml","form_type":"4/A","original_submission_date":"2022-11-28"}},{"id":2081412,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-19T07:08:15.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":600,"price":1.1,"value":660.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error."}],"balance_after":9316,"source":{"system":"sec-edgar","filing":"0001415889-22-012650","document":"form4a-12192022_121206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922012650/form4a-12192022_121206.xml","form_type":"4/A","original_submission_date":"2022-11-28"}},{"id":2081411,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-19T07:08:15.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":8716,"price":1.12,"value":9761.92,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error."}],"balance_after":8716,"source":{"system":"sec-edgar","filing":"0001415889-22-012650","document":"form4a-12192022_121206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922012650/form4a-12192022_121206.xml","form_type":"4/A","original_submission_date":"2022-11-28"}},{"id":2091030,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-12-09T16:33:05.000Z","date":"2022-12-07","kind":"sale","acquired":false,"shares":400000,"price":1,"value":400000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc.  Purchaser has agreed to hold the shares for a period of one year."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Jonathan Javitt Living Trust.  The Reporting Person is a trustee of the Trust."}],"balance_after":12899997,"source":{"system":"sec-edgar","filing":"0001415889-22-012324","document":"form4-12092022_091256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000141588922012324/form4-12092022_091256.xml","form_type":"4"}},{"id":2100185,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock","published_at":"2022-12-01T19:29:11.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":8441,"price":1.5046,"value":12700.3286,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9634793,"source":{"system":"sec-edgar","filing":"0000880984-22-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000017/primary_doc.xml","form_type":"4"}},{"id":2100184,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock","published_at":"2022-12-01T19:29:11.000Z","date":"2022-11-29","kind":"sale","acquired":false,"shares":13730,"price":1.5041,"value":20651.293,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9643234,"source":{"system":"sec-edgar","filing":"0000880984-22-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000017/primary_doc.xml","form_type":"4"}},{"id":2102640,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":1750,"price":1.25,"value":2187.5,"ownership":{"direct":true},"balance_after":1750,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102639,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.24,"value":3100.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":40209,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102638,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":37709,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102637,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":40209,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102636,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":37709,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2103276,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-28T07:42:26.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":7021,"price":1.11,"value":7793.31,"ownership":{"direct":false,"nature":"Shares purchased though 401(k) plan"},"balance_after":16377,"source":{"system":"sec-edgar","filing":"0001415889-22-011778","document":"form4-11282022_121119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922011778/form4-11282022_121119.xml","form_type":"4"}},{"id":2103275,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-28T07:42:26.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":600,"price":1.1,"value":660.0,"ownership":{"direct":false,"nature":"Shares purchased though 401(k) plan"},"balance_after":9316,"source":{"system":"sec-edgar","filing":"0001415889-22-011778","document":"form4-11282022_121119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922011778/form4-11282022_121119.xml","form_type":"4"}},{"id":2103274,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121460,"kind":"person","name":"VAN VOORHEES SETH","position":1,"cik":"0001284934","reported_name":"VAN VOORHEES SETH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-28T07:42:26.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":8716,"price":1.12,"value":9761.92,"ownership":{"direct":false,"nature":"Shares purchased though 401(k) plan"},"balance_after":8716,"source":{"system":"sec-edgar","filing":"0001415889-22-011778","document":"form4-11282022_121119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1284934/000141588922011778/form4-11282022_121119.xml","form_type":"4"}},{"id":2104879,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:09:34.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":40408,"price":1.1,"value":44448.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10."}],"balance_after":500000,"source":{"system":"sec-edgar","filing":"0000950142-22-003250","document":"es220307715_4a-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003250/es220307715_4a-hurvitz.xml","form_type":"4/A","original_submission_date":"2022-11-21"}},{"id":2104878,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:09:34.000Z","date":"2022-11-17","kind":"purchase","acquired":true,"shares":171780,"price":1.08,"value":185522.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":459592,"source":{"system":"sec-edgar","filing":"0000950142-22-003250","document":"es220307715_4a-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003250/es220307715_4a-hurvitz.xml","form_type":"4/A","original_submission_date":"2022-11-21"}},{"id":2104877,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:09:34.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":287812,"price":0.99,"value":284933.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":287812,"source":{"system":"sec-edgar","filing":"0000950142-22-003250","document":"es220307715_4a-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003250/es220307715_4a-hurvitz.xml","form_type":"4/A","original_submission_date":"2022-11-21"}},{"id":2107145,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-22T17:46:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."}],"balance_after":162660,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003244","document":"es220307157_4-gorovitz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014222003244/es220307157_4-gorovitz.xml","form_type":"4"}},{"id":2107144,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":122139,"kind":"person","name":"Glied Sharon","position":1,"cik":"0001864538","reported_name":"Glied Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-22T17:45:45.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."}],"balance_after":228097,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003243","document":"es220307156_4-glied.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864538/000095014222003243/es220307156_4-glied.xml","form_type":"4"}},{"id":2107146,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-22T17:44:53.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."}],"balance_after":162660,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003242","document":"es220307154_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014222003242/es220307154_4-flynnp.xml","form_type":"4"}},{"id":2108188,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-21T17:58:23.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer."}],"balance_after":381083,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003233","document":"es220307158_4-hurvitz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003233/es220307158_4-hurvitz.xml","form_type":"4"}},{"id":2108187,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T17:58:23.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":40408,"price":1.1,"value":44448.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common"}],"balance_after":500000,"source":{"system":"sec-edgar","filing":"0000950142-22-003233","document":"es220307158_4-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003233/es220307158_4-hurvitz.xml","form_type":"4"}},{"id":2108186,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T17:58:23.000Z","date":"2022-11-17","kind":"purchase","acquired":true,"shares":171780,"price":1.08,"value":185522.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":459592,"source":{"system":"sec-edgar","filing":"0000950142-22-003233","document":"es220307158_4-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003233/es220307158_4-hurvitz.xml","form_type":"4"}},{"id":2108185,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T17:58:23.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":287812,"price":0.99,"value":284933.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average purchase price per share of common stock (the \"Common Stock\"), of NRx Pharmaceuticals, Inc. (the \"Issuer\"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."}],"balance_after":287812,"source":{"system":"sec-edgar","filing":"0000950142-22-003233","document":"es220307158_4-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014222003233/es220307158_4-hurvitz.xml","form_type":"4"}},{"id":2110521,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock","published_at":"2022-11-18T19:05:42.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":33018,"price":1.0523,"value":34744.8414,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9656964,"source":{"system":"sec-edgar","filing":"0000880984-22-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000015/primary_doc.xml","form_type":"4"}},{"id":2110520,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock","published_at":"2022-11-18T19:05:42.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":133719,"price":1.02,"value":136393.38,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9689982,"source":{"system":"sec-edgar","filing":"0000880984-22-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000015/primary_doc.xml","form_type":"4"}},{"id":2116384,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock","published_at":"2022-11-15T19:40:31.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":49200,"price":1.0063,"value":49509.96,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9823701,"source":{"system":"sec-edgar","filing":"0000880984-22-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000014/primary_doc.xml","form_type":"4"}},{"id":2197848,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-02T17:43:36.000Z","date":"2022-07-29","kind":"sale","acquired":false,"shares":784063,"price":1.0094,"value":791433.1922,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":9872901,"source":{"system":"sec-edgar","filing":"0000880984-22-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000009/primary_doc.xml","form_type":"4"}},{"id":2215005,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T17:06:15.000Z","date":"2022-07-01","kind":"gift","acquired":false,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were gifted to a charitable remainder unitrust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":10656964,"source":{"system":"sec-edgar","filing":"0000880984-22-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000008/primary_doc.xml","form_type":"4"}},{"id":2240441,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T20:11:10.000Z","date":"2022-06-07","kind":"sale","acquired":false,"shares":86459,"price":0.6461,"value":55861.1599,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":12656964,"source":{"system":"sec-edgar","filing":"0000880984-22-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000007/primary_doc.xml","form_type":"4"}},{"id":2240440,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T20:11:10.000Z","date":"2022-06-06","kind":"sale","acquired":false,"shares":115657,"price":0.6653,"value":76946.6021,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":12743423,"source":{"system":"sec-edgar","filing":"0000880984-22-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000007/primary_doc.xml","form_type":"4"}},{"id":2240439,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T20:11:10.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":243596,"price":0.7024,"value":171101.8304,"ownership":{"direct":false,"nature":"by Glytech LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by Glytech LLC of which the Reporting Person is the sole owner."}],"balance_after":12859080,"source":{"system":"sec-edgar","filing":"0000880984-22-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000088098422000007/primary_doc.xml","form_type":"4"}},{"id":2247247,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2022-06-02T09:46:10.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":100000,"price":0.58,"value":58000.0,"ownership":{"direct":true},"balance_after":146332,"source":{"system":"sec-edgar","filing":"0000921895-22-001874","document":"form4a13398002_06022022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000092189522001874/form4a13398002_06022022.xml","form_type":"4/A","original_submission_date":"2022-06-02"}},{"id":2247243,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2022-06-02T08:55:21.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":100000,"price":58,"value":5800000.0,"ownership":{"direct":true},"balance_after":146332,"source":{"system":"sec-edgar","filing":"0000921895-22-001872","document":"form413398002_06012022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000092189522001872/form413398002_06012022.xml","form_type":"4"}},{"id":2340069,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option","published_at":"2022-03-10T16:04:19.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":100000,"price":2.61,"value":261000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc."}],"balance_after":347200,"derivative":{"exercise_price":2.61,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950142-22-000997","document":"es220233694_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014222000997/es220233694_4-besthof.xml","form_type":"4"}},{"id":2529119,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":30095,"kind":"person","name":"McMaster Herbert Raymond","position":1,"cik":"0001811490","reported_name":"McMaster Herbert Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-11-02T20:07:26.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":10424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":10424,"derivative":{"underlying":"Common Stock","underlying_shares":10424},"source":{"system":"sec-edgar","filing":"0000950142-21-003506","document":"es210197025_4-mcmaster.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811490/000095014221003506/es210197025_4-mcmaster.xml","form_type":"4"}},{"id":2529118,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":30095,"kind":"person","name":"McMaster Herbert Raymond","position":1,"cik":"0001811490","reported_name":"McMaster Herbert Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T20:07:26.000Z","date":"2021-08-26","kind":"exercise","acquired":false,"shares":28724,"price":2.22,"value":63767.28,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested."}],"balance_after":16362,"derivative":{"exercise_price":2.22,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":28724},"source":{"system":"sec-edgar","filing":"0000950142-21-003506","document":"es210197025_4-mcmaster.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811490/000095014221003506/es210197025_4-mcmaster.xml","form_type":"4"}},{"id":2529117,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":30095,"kind":"person","name":"McMaster Herbert Raymond","position":1,"cik":"0001811490","reported_name":"McMaster Herbert Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T20:07:26.000Z","date":"2021-08-26","kind":"exercise","acquired":true,"shares":18300,"price":2.22,"value":40626.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The options are fully vested."}],"balance_after":18300,"source":{"system":"sec-edgar","filing":"0000950142-21-003506","document":"es210197025_4-mcmaster.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811490/000095014221003506/es210197025_4-mcmaster.xml","form_type":"4"}},{"id":2529245,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T16:06:27.000Z","date":"2021-07-16","kind":"gift","acquired":false,"shares":434594,"ownership":{"direct":false,"nature":"By Glytech LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Irrevocable gift by way of transfer to certain trusts established for the benefit of the Reporting Person's immediate family members. Neither the Reporting Person nor Glytech LLC received any compensation in respect of such transfers. Upon completion of such transfers, both the Reporting Person and Glytech LLC ceased to have any beneficial ownership or other interest in the shares subject to the transfers."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech, LLC of which the Reporting Person is the sole owner."}],"balance_after":13102676,"source":{"system":"sec-edgar","filing":"0000950142-21-003505","document":"es210197024_4-javittd.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000095014221003505/es210197024_4-javittd.xml","form_type":"4"}},{"id":2529244,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T16:06:27.000Z","date":"2021-07-16","kind":"gift","acquired":false,"shares":434594,"ownership":{"direct":false,"nature":"By Glytech LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Irrevocable gift by way of transfer to certain trusts established for the benefit of the Reporting Person's immediate family members. Neither the Reporting Person nor Glytech LLC received any compensation in respect of such transfers. Upon completion of such transfers, both the Reporting Person and Glytech LLC ceased to have any beneficial ownership or other interest in the shares subject to the transfers."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Glytech, LLC of which the Reporting Person is the sole owner."}],"balance_after":13537270,"source":{"system":"sec-edgar","filing":"0000950142-21-003505","document":"es210197024_4-javittd.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000095014221003505/es210197024_4-javittd.xml","form_type":"4"}},{"id":2529255,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":7502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":33603,"derivative":{"underlying":"Common Stock","underlying_shares":7502},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529254,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":10496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":26101,"derivative":{"underlying":"Common Stock","underlying_shares":10496},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529253,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":20666,"price":3.07,"value":63444.62,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"From an option grant dated November 15, 2020; subject to certain conditions, the options will generally vest at a rate of 2066 every month commencing on 11/30/2020 through 10/30/1022 and the final 2,082 shares on 11/30/2022. As of September 1, 2021, 20,666 shares had vested and were available for exercise."}],"balance_after":28934,"derivative":{"exercise_price":3.07,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":20666},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529252,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":28916,"price":3.07,"value":88772.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise."}],"balance_after":71924,"derivative":{"exercise_price":3.07,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":28916},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529251,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"grant","acquired":true,"shares":15605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":15605,"derivative":{"underlying":"Common Stock","underlying_shares":15605},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529250,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"exercise","acquired":false,"shares":43000,"price":3.07,"value":132010.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise."}],"balance_after":100840,"derivative":{"exercise_price":3.07,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529249,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":13164,"price":3.07,"value":40413.48,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":31584,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529248,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":18420,"price":3.07,"value":56549.4,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":18420,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529247,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":33715,"price":13.11,"value":442003.65,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529246,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"exercise","acquired":true,"shares":27395,"price":3.07,"value":84102.65,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":33715,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529259,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"grant","acquired":true,"shares":36290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":36290,"derivative":{"underlying":"Common Stock","underlying_shares":36290},"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529258,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":100000,"price":0.2,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested."}],"balance_after":247200,"derivative":{"exercise_price":0.2,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529257,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Common Stock","published_at":"2021-11-02T16:04:47.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":40000,"price":11.76,"value":470400.0,"ownership":{"direct":true},"balance_after":23710,"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529256,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Common Stock","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":63710,"price":0.2,"value":12742.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The options are fully vested."}],"balance_after":63710,"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2673244,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T22:46:28.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":99200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, the options will generally vest in 36 equal installments every month commencing on 11/30/20 and fully vesting on 11/30/23."}],"balance_after":198400,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-14","underlying":"Common Stock","underlying_shares":99200},"source":{"system":"sec-edgar","filing":"0000950142-21-001939","document":"es210157183_4-fricker.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221001939/es210157183_4-fricker.xml","form_type":"4"}},{"id":2673243,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138410,"kind":"person","name":"Fricker William","position":1,"cik":"0001752213","reported_name":"Fricker William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T22:46:28.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":99200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":99200,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-14","underlying":"Common Stock","underlying_shares":99200},"source":{"system":"sec-edgar","filing":"0000950142-21-001939","document":"es210157183_4-fricker.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221001939/es210157183_4-fricker.xml","form_type":"4"}},{"id":2673417,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138413,"kind":"person","name":"Troy Daniel","position":1,"cik":"0001555848","reported_name":"Troy Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:48:57.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":65437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":65437,"derivative":{"exercise_price":2.18,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":65437},"source":{"system":"sec-edgar","filing":"0000950142-21-001946","document":"es210157191_4-troy.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555848/000095014221001946/es210157191_4-troy.xml","form_type":"4"}},{"id":2673416,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138413,"kind":"person","name":"Troy Daniel","position":1,"cik":"0001555848","reported_name":"Troy Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:48:57.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":43093,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."}],"balance_after":43093,"source":{"system":"sec-edgar","filing":"0000950142-21-001946","document":"es210157191_4-troy.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555848/000095014221001946/es210157191_4-troy.xml","form_type":"4"}},{"id":2673767,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":1422000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by The Javitt 2012 Irrevocable Dynasty Trust of which the Reporting Person is the Grantor."}],"balance_after":1422000,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}},{"id":2673766,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":13348997,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Jonathan Javitt Living Trust of which the Reporting Person is trustee."}],"balance_after":13348997,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}},{"id":2673765,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75570,"kind":"person","name":"Javitt Jonathan C","position":1,"cik":"0001303782","reported_name":"Javitt Jonathan C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T18:48:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":46332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger."}],"balance_after":46332,"source":{"system":"sec-edgar","filing":"0000950142-21-001945","document":"es210157190_4-javittj.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1303782/000095014221001945/es210157190_4-javittj.xml","form_type":"4"}},{"id":2674211,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":121957,"kind":"person","name":"Javitt Daniel C.","position":1,"cik":"0001864534","reported_name":"Javitt Daniel C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:48:09.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":13971864,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Glytech, LLC of which the Reporting Person is the sole owner."}],"balance_after":13971864,"source":{"system":"sec-edgar","filing":"0000950142-21-001944","document":"es210157189_4-javittd.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864534/000095014221001944/es210157189_4-javittd.xml","form_type":"4"}},{"id":2673294,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to buy)","published_at":"2021-06-10T18:47:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":218423,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Shirat HaChaim Ltd. of which the Reporting Person is the sole owner."}],"balance_after":218423,"derivative":{"exercise_price":1.53,"expiration_date":"2021-09-01","underlying":"Common Stock","underlying_shares":218423},"source":{"system":"sec-edgar","filing":"0000950142-21-001942","document":"es210157187_4-hurvitz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014221001942/es210157187_4-hurvitz.xml","form_type":"4"}},{"id":2673293,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":208443,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by CH Health-Private Venture Capital Ltd. of which the Reporting Person is the sole owner."}],"balance_after":208443,"source":{"system":"sec-edgar","filing":"0000950142-21-001942","document":"es210157187_4-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014221001942/es210157187_4-hurvitz.xml","form_type":"4"}},{"id":2673292,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75568,"kind":"person","name":"Hurvitz Chaim","position":1,"cik":"0001630542","reported_name":"Hurvitz Chaim","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:35.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":1436350,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Shirat HaChaim Ltd. of which the Reporting Person is the sole owner."}],"balance_after":1436350,"source":{"system":"sec-edgar","filing":"0000950142-21-001942","document":"es210157187_4-hurvitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630542/000095014221001942/es210157187_4-hurvitz.xml","form_type":"4"}},{"id":2674217,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":16678,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674216,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Marisa Shey Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674215,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Jeremy Paul Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674214,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Samuel David Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674210,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":122139,"kind":"person","name":"Glied Sharon","position":1,"cik":"0001864538","reported_name":"Glied Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:46:53.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":65437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":65437,"derivative":{"exercise_price":0.21,"expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":65437},"source":{"system":"sec-edgar","filing":"0000950142-21-001940","document":"es210157184_4-glied.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864538/000095014221001940/es210157184_4-glied.xml","form_type":"4"}},{"id":2674209,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":122139,"kind":"person","name":"Glied Sharon","position":1,"cik":"0001864538","reported_name":"Glied Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:53.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":13168,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Cottingham-Hillcrest, Inc. of which the Reporting Person has a controlling interest."}],"balance_after":13168,"source":{"system":"sec-edgar","filing":"0000950142-21-001940","document":"es210157184_4-glied.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864538/000095014221001940/es210157184_4-glied.xml","form_type":"4"}},{"id":2674226,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to buy)","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":692639,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":692639,"derivative":{"exercise_price":3.08,"expiration_date":"2025-10-22","underlying":"Common Stock","underlying_shares":692639},"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674225,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to buy)","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":692639,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":692639,"derivative":{"exercise_price":3.08,"expiration_date":"2025-10-22","underlying":"Common Stock","underlying_shares":692639},"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674224,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":35209,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":35209,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674223,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":35209,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":35209,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674222,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":362332,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Nash-Flynn Investments, LLC of which the Reporting Person is the sole member."}],"balance_after":362332,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674221,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":148800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to certain conditions, the options will generally vest in twenty four equal installments every month commencing on 04/30/21 and fully vesting on 04/30/23."}],"balance_after":148800,"derivative":{"exercise_price":72.3,"expiration_date":"2031-04-21","underlying":"Common Stock","underlying_shares":148800},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674220,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":49600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to certain conditions, the options will generally vest at a rate of 416 every month commencing on 11/30/20 through 10/30/22 and the final 432 shares on 11/30/22."}],"balance_after":49600,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":49600},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674219,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":143840,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to certain conditions, the options will generally vest in twenty four equal installments every month commencing on 09/30/20 and fully vesting on 09/30/22."}],"balance_after":143840,"derivative":{"exercise_price":3.08,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":143840},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674218,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":6320,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."}],"balance_after":6320,"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674213,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:44:45.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":347200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."}],"balance_after":347200,"derivative":{"exercise_price":3.08,"expiration_date":"2030-10-23","underlying":"Common Stock","underlying_shares":347200},"source":{"system":"sec-edgar","filing":"0000950142-21-001936","document":"es210157180_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221001936/es210157180_4-besthof.xml","form_type":"4"}},{"id":2674212,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:44:45.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":347200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":347200,"derivative":{"exercise_price":0.21,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":347200},"source":{"system":"sec-edgar","filing":"0000950142-21-001936","document":"es210157180_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221001936/es210157180_4-besthof.xml","form_type":"4"}},{"id":2681093,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":138644,"kind":"organization","name":"BRAC Lending Group LLC","position":1,"cik":"0001759828","reported_name":"BRAC Lending Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T09:40:44.000Z","date":"2021-05-24","kind":"disposition_to_issuer","acquired":false,"shares":869565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Form 4 filed on May 25, 2021, erroneously reported 562,435 shares beneficially owned in Column 5. This amendment is being filed to correct the total shares beneficially owned in Column 5."}],"balance_after":590435,"source":{"system":"sec-edgar","filing":"0001094891-21-000243","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759828/000109489121000243/edgar.xml","form_type":"4/A","original_submission_date":"2021-05-25"}},{"id":2696484,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":139051,"kind":"organization","name":"Big Rock Partners Sponsor, LLC","position":1,"cik":"0001723217","reported_name":"Big Rock Partners Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139052,"kind":"person","name":"ACKERMAN RICHARD","position":2,"cik":"0001724016","reported_name":"ACKERMAN RICHARD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President & CEO"}}],"security":"Unit Purchase Option","published_at":"2021-05-26T01:17:34.000Z","date":"2021-05-24","kind":"purchase","acquired":true,"shares":100000,"price":1,"value":100000.0,"ownership":{"direct":false,"nature":"By A/Z Property Partners LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Ackerman is the majority owner of this entity and may be deemed to have beneficial ownership of the shares owned thereby. Mr. Ackerman disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":100000,"derivative":{"exercise_price":10,"exercise_date":"2021-05-24","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001094891-21-000212","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000109489121000212/edgar.xml","form_type":"4"}},{"id":2696483,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":139051,"kind":"organization","name":"Big Rock Partners Sponsor, LLC","position":1,"cik":"0001723217","reported_name":"Big Rock Partners Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139052,"kind":"person","name":"ACKERMAN RICHARD","position":2,"cik":"0001724016","reported_name":"ACKERMAN RICHARD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President & CEO"}}],"security":"Rights, exchangeable for Common Stock","published_at":"2021-05-26T01:17:34.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":272500,"ownership":{"direct":false,"nature":"By Big Rock Partners Sponsor, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each of the Issuer's Rights were convertible into 1/10 of one share of the Issuer's common stock upon consummation of the Issuer's initial business combination and had no expiration\ndate. In connection with the Issuer's business combination, such Rights automatically converted into shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each of the Issuer's Rights were convertible into 1/10 of one share of the Issuer's common stock upon consummation of the Issuer's initial business combination and had no expiration\ndate. In connection with the Issuer's business combination, such Rights automatically converted into shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each of the Issuer's Rights were convertible into 1/10 of one share of the Issuer's common stock upon consummation of the Issuer's initial business combination and had no expiration\ndate. In connection with the Issuer's business combination, such Rights automatically converted into shares of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each of the Issuer's Rights were convertible into 1/10 of one share of the Issuer's common stock upon consummation of the Issuer's initial business combination and had no expiration\ndate. In connection with the Issuer's business combination, such Rights automatically converted into shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Ackerman is the managing member of this entity and has the sole voting and dispositive power of the securities held thereby. Accordingly, Mr. Ackerman may be deemed to have beneficial ownership of such shares. Mr. Ackerman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27250},"source":{"system":"sec-edgar","filing":"0001094891-21-000212","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000109489121000212/edgar.xml","form_type":"4"}},{"id":2696482,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":139051,"kind":"organization","name":"Big Rock Partners Sponsor, LLC","position":1,"cik":"0001723217","reported_name":"Big Rock Partners Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139052,"kind":"person","name":"ACKERMAN RICHARD","position":2,"cik":"0001724016","reported_name":"ACKERMAN RICHARD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-05-26T01:17:34.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":27250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Big Rock Partners Sponsor, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Ackerman is the managing member of this entity and has the sole voting and dispositive power of the securities held thereby. Accordingly, Mr. Ackerman may be deemed to have beneficial ownership of such shares. Mr. Ackerman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":519315,"source":{"system":"sec-edgar","filing":"0001094891-21-000212","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1719406/000109489121000212/edgar.xml","form_type":"4"}}],"next_cursor":"2021-05-26T01:17:34.000000Z,2696482"}